<p>Solid Biosciences Inc.（纳斯达克代码：SLDB - 获取免费报告）首席技术官 Paul Herzich 于 12 月 3 日（星期三）出售了 2,701 股该股票。股票的平均售价为 5.11 美元，总交易额为 13,802.11 美元。出售完成后，首席技术官直接持有该公司 26,622 股，估值约为 136,038.42 美元。此次交易使其持股比例减少了 9.21%。该出售在向美国证券交易委员会（SEC）的备案中披露，相关信息可在 SEC 网站上查阅。</p>
<p>获取 <strong>Solid Biosciences</strong> 警报：</p>
<h2>Solid Biosciences 价格表现</h2>
<ul>
<li>Sarepta 在 2025 年遭遇重创——分析师仍然预测 179% 的上涨空间</li>
</ul>
<p>在周四的交易时段，纳斯达克：SLDB 上涨 0.73 美元，达到 5.92 美元。该股票的交易量为 1,597,041 股，而其平均交易量为 1,655,025 股。该公司的市值为 4.6123 亿美元，市盈率为-2.38，贝塔值为 2.97。Solid Biosciences Inc.的股价在过去一年内最低为 2.41 美元，最高为 7.37 美元。该公司的 50 日简单移动平均线为 5.34 美元，200 日简单移动平均线为 5.26 美元。</p>
<p>Solid Biosciences（纳斯达克：SLDB - 获取免费报告）最近于 11 月 3 日（星期一）发布了季度财报。公司报告每股收益（EPS）为-0.48 美元，低于市场共识预期的-0.42 美元，差距为 0.06 美元。股票研究分析师预计 Solid Biosciences Inc.在当前年度的每股收益将为-2.84 美元。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>Sarepta 因致死事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
<p>几位分析师最近对 SLDB 股票发表了看法。摩根大通将 Solid Biosciences 的目标价从 13.00 美元下调至 11.00 美元，并在 11 月 5 日的研究报告中给予该股票 “增持” 评级。Chardan Capital 在 11 月 4 日的研究报告中重申了对 Solid Biosciences 的 “买入” 评级，并设定了 15.00 美元的目标价。Needham &amp; Company LLC 在周四的研究报告中开始覆盖 Solid Biosciences，给予 “买入” 评级和 16.00 美元的目标价。Wall Street Zen 在 10 月 19 日的报告中将 Solid Biosciences 的评级从 “持有” 下调至 “卖出”。最后，巴克莱在 11 月 4 日的报告中设定了 Solid Biosciences 的目标价为 9.00 美元，并给予该股票 “增持” 评级。一位研究分析师给予该股票 “强烈买入” 评级，十一位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 14.82 美元。</p>
<p><strong>查看我们关于 SLDB 的最新报告</strong></p>
<h2>Solid Biosciences 的机构交易</h2>
<ul>
<li>Solid Biosciences 能否在 DMD 市场挑战 Sarepta？</li>
</ul>
<p>一些机构投资者和对冲基金最近调整了对 SLDB 的持股。Bain Capital Life Sciences Investors LLC 在第一季度将其在 Solid Biosciences 的持股增加了 96.1%。Bain Capital Life Sciences Investors LLC 现在拥有 7,911,669 股该公司的股票，价值 29,273,000 美元，此前在上个季度又购买了 3,877,087 股。Siren L.L.C.在第一季度将其在 Solid Biosciences 的持股增加了 97.8%。Siren L.L.C.现在拥有 7,415,905 股该公司的股票，价值 27,439,000 美元，此前在上个季度又购买了 3,666,864 股。Adage Capital Partners GP L.L.C.在第一季度将其在 Solid Biosciences 的持股增加了 285.0%。Adage Capital Partners GP L.L.C.现在拥有 6,729,484 股该公司的股票，价值 24,899,000 美元，此前在上个季度又购买了 4,981,400 股。Vestal Point Capital LP 在第三季度将其在 Solid Biosciences 的持股增加了 97.7%。Vestal Point Capital LP 现在拥有 2,975,000 股该公司的股票，价值 18,356,000 美元，此前在上个季度又购买了 1,470,000 股。最后，Redmile Group LLC 在第一季度将其在 Solid Biosciences 的持股增加了 228.2%。Redmile Group LLC 现在拥有 2,019,171 股该公司的股票，价值 7,471,000 美元，此前在上个季度又收购了 1,403,925 股。机构投资者持有该公司 81.46% 的股票。</p>
<h2>Solid Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Solid Biosciences Inc.是一家生命科学公司，专注于开发用于治疗美国的神经肌肉和心脏疾病的疗法。该公司的主要产品候选药物是 SGT-003，一种用于治疗杜氏肌营养不良症的基因转移候选药物；以及 SGT-501，用于治疗儿茶酚胺多态性室性心动过速。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Solid Biosciences</li>
<li>如何在 5 个简单步骤中做空一只股票</li>
<li>利用 2026 年人工智能基础设施的增长，投资这只高增长 ETF</li>
<li>3 只 REIT 值得长期持有</li>
<li>强劲的季度表现，反应平平：为什么 GitLab 的股价下跌</li>
<li>为什么特别股息对收入投资者来说可能是一个令人愉快的惊喜</li>
<li>特斯拉开始 12 月的三个迹象</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Solid Biosciences 吗？</h2>
<p>在你考虑投资 Solid Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Solid Biosciences 并不在名单上。</p>
<p>虽然 Solid Biosciences 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SLDB

<p>Solid Biosciences 首席技术官 Paul Herzich 以每股 5.11 美元的价格出售了 2,701 股，总计 13,802.11 美元，减少了 9.21% 的持股比例。出售后，他持有 26,622 股，价值 136,038.42 美元。此次出售在美国证券交易委员会的备案中披露。SLDB 股票上涨至 5.92 美元，市值为 4.6123 亿美元。分析师的评级意见不一，普遍持中性买入的共识，目标价格为 14.82 美元。机构投资者持有 SLDB 股票的 81.46%，近期持股显著增加</p>

<p>Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CTO Paul Herzich sold 2,701 shares of the stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $5.11, for a total transaction of $13,802.11. Following the completion of the sale, the chief technology officer directly owned 26,622 shares in the company, valued at approximately $136,038.42. The trade was a 9.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.</p>
<div class="lb-trans"><p>Solid Biosciences Inc.（纳斯达克代码：SLDB - 获取免费报告）首席技术官 Paul Herzich 于 12 月 3 日（星期三）出售了 2,701 股该股票。股票的平均售价为 5.11 美元，总交易额为 13,802.11 美元。出售完成后，首席技术官直接持有该公司 26,622 股，估值约为 136,038.42 美元。此次交易使其持股比例减少了 9.21%。该出售在向美国证券交易委员会（SEC）的备案中披露，相关信息可在 SEC 网站上查阅。</p>
</div><p>Get <strong>Solid Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Solid Biosciences</strong> 警报：</p>
</div><h2>Solid Biosciences Price Performance</h2>
<div class="lb-trans"><h2>Solid Biosciences 价格表现</h2>
</div><ul>
<li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 在 2025 年遭遇重创——分析师仍然预测 179% 的上涨空间</li>
</ul>
</div><p>NASDAQ:SLDB traded up $0.73 during trading hours on Thursday, hitting $5.92. The stock had a trading volume of 1,597,041 shares, compared to its average volume of 1,655,025. The firm has a market capitalization of $461.23 million, a price-to-earnings ratio of -2.38 and a beta of 2.97. Solid Biosciences Inc. has a one year low of $2.41 and a one year high of $7.37. The company has a 50 day simple moving average of $5.34 and a two-hundred day simple moving average of $5.26.</p>
<div class="lb-trans"><p>在周四的交易时段，纳斯达克：SLDB 上涨 0.73 美元，达到 5.92 美元。该股票的交易量为 1,597,041 股，而其平均交易量为 1,655,025 股。该公司的市值为 4.6123 亿美元，市盈率为-2.38，贝塔值为 2.97。Solid Biosciences Inc.的股价在过去一年内最低为 2.41 美元，最高为 7.37 美元。该公司的 50 日简单移动平均线为 5.34 美元，200 日简单移动平均线为 5.26 美元。</p>
</div><p>Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.06). Equities research analysts anticipate that Solid Biosciences Inc. will post -2.84 earnings per share for the current year.</p>
<div class="lb-trans"><p>Solid Biosciences（纳斯达克：SLDB - 获取免费报告）最近于 11 月 3 日（星期一）发布了季度财报。公司报告每股收益（EPS）为-0.48 美元，低于市场共识预期的-0.42 美元，差距为 0.06 美元。股票研究分析师预计 Solid Biosciences Inc.在当前年度的每股收益将为-2.84 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta 因致死事件下跌 42%；市场关注 Solid Biosciences</li>
</ul>
</div><p>Several analysts have recently weighed in on SLDB shares. JPMorgan Chase &amp; Co. lowered their price objective on shares of Solid Biosciences from $13.00 to $11.00 and set an &#34;overweight&#34; rating on the stock in a research report on Wednesday, November 5th. Chardan Capital reissued a &#34;buy&#34; rating and set a $15.00 price objective on shares of Solid Biosciences in a research note on Tuesday, November 4th. Needham &amp; Company LLC assumed coverage on Solid Biosciences in a research note on Thursday. They issued a &#34;buy&#34; rating and a $16.00 target price on the stock. Wall Street Zen cut shares of Solid Biosciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Sunday, October 19th. Finally, Barclays set a $9.00 target price on Solid Biosciences and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $14.82.</p>
<div class="lb-trans"><p>几位分析师最近对 SLDB 股票发表了看法。摩根大通将 Solid Biosciences 的目标价从 13.00 美元下调至 11.00 美元，并在 11 月 5 日的研究报告中给予该股票 “增持” 评级。Chardan Capital 在 11 月 4 日的研究报告中重申了对 Solid Biosciences 的 “买入” 评级，并设定了 15.00 美元的目标价。Needham &amp; Company LLC 在周四的研究报告中开始覆盖 Solid Biosciences，给予 “买入” 评级和 16.00 美元的目标价。Wall Street Zen 在 10 月 19 日的报告中将 Solid Biosciences 的评级从 “持有” 下调至 “卖出”。最后，巴克莱在 11 月 4 日的报告中设定了 Solid Biosciences 的目标价为 9.00 美元，并给予该股票 “增持” 评级。一位研究分析师给予该股票 “强烈买入” 评级，十一位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 14.82 美元。</p>
</div><p><strong>View Our Latest Report on SLDB</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 SLDB 的最新报告</strong></p>
</div><h2>Institutional Trading of Solid Biosciences</h2>
<div class="lb-trans"><h2>Solid Biosciences 的机构交易</h2>
</div><ul>
<li>Can Solid Biosciences Challenge Sarepta in the DMD Market?</li>
</ul>
<div class="lb-trans"><ul>
<li>Solid Biosciences 能否在 DMD 市场挑战 Sarepta？</li>
</ul>
</div><p>A number of institutional investors and hedge funds have recently modified their holdings of SLDB. Bain Capital Life Sciences Investors LLC increased its holdings in Solid Biosciences by 96.1% in the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company's stock worth $29,273,000 after buying an additional 3,877,087 shares in the last quarter. Siren L.L.C. increased its holdings in Solid Biosciences by 97.8% during the first quarter. Siren L.L.C. now owns 7,415,905 shares of the company's stock valued at $27,439,000 after buying an additional 3,666,864 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of Solid Biosciences by 285.0% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 6,729,484 shares of the company's stock worth $24,899,000 after purchasing an additional 4,981,400 shares in the last quarter. Vestal Point Capital LP increased its position in Solid Biosciences by 97.7% in the third quarter. Vestal Point Capital LP now owns 2,975,000 shares of the company's stock worth $18,356,000 after buying an additional 1,470,000 shares in the last quarter. Finally, Redmile Group LLC increased its holdings in Solid Biosciences by 228.2% in the 1st quarter. Redmile Group LLC now owns 2,019,171 shares of the company's stock worth $7,471,000 after acquiring an additional 1,403,925 shares in the last quarter. Institutional investors own 81.46% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近调整了对 SLDB 的持股。Bain Capital Life Sciences Investors LLC 在第一季度将其在 Solid Biosciences 的持股增加了 96.1%。Bain Capital Life Sciences Investors LLC 现在拥有 7,911,669 股该公司的股票，价值 29,273,000 美元，此前在上个季度又购买了 3,877,087 股。Siren L.L.C.在第一季度将其在 Solid Biosciences 的持股增加了 97.8%。Siren L.L.C.现在拥有 7,415,905 股该公司的股票，价值 27,439,000 美元，此前在上个季度又购买了 3,666,864 股。Adage Capital Partners GP L.L.C.在第一季度将其在 Solid Biosciences 的持股增加了 285.0%。Adage Capital Partners GP L.L.C.现在拥有 6,729,484 股该公司的股票，价值 24,899,000 美元，此前在上个季度又购买了 4,981,400 股。Vestal Point Capital LP 在第三季度将其在 Solid Biosciences 的持股增加了 97.7%。Vestal Point Capital LP 现在拥有 2,975,000 股该公司的股票，价值 18,356,000 美元，此前在上个季度又购买了 1,470,000 股。最后，Redmile Group LLC 在第一季度将其在 Solid Biosciences 的持股增加了 228.2%。Redmile Group LLC 现在拥有 2,019,171 股该公司的股票，价值 7,471,000 美元，此前在上个季度又收购了 1,403,925 股。机构投资者持有该公司 81.46% 的股票。</p>
</div><h2>Solid Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Solid Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.</p>
<div class="lb-trans"><p>Solid Biosciences Inc.是一家生命科学公司，专注于开发用于治疗美国的神经肌肉和心脏疾病的疗法。该公司的主要产品候选药物是 SGT-003，一种用于治疗杜氏肌营养不良症的基因转移候选药物；以及 SGT-501，用于治疗儿茶酚胺多态性室性心动过速。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Solid Biosciences</li>
<li>How to Short a Stock in 5 Easy Steps</li>
<li>Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF</li>
<li>3 REITs to Buy and Hold for the Long Term</li>
<li>Strong Quarter, Weak Reaction: Why GitLab Shares Dropped</li>
<li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li>
<li>3 Signs Tesla Is Starting December on the Front Foot</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Solid Biosciences</li>
<li>如何在 5 个简单步骤中做空一只股票</li>
<li>利用 2026 年人工智能基础设施的增长，投资这只高增长 ETF</li>
<li>3 只 REIT 值得长期持有</li>
<li>强劲的季度表现，反应平平：为什么 GitLab 的股价下跌</li>
<li>为什么特别股息对收入投资者来说可能是一个令人愉快的惊喜</li>
<li>特斯拉开始 12 月的三个迹象</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=SLDB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Solid Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Solid Biosciences 吗？</h2>
</div><p>Before you consider Solid Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Solid Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Solid Biosciences 并不在名单上。</p>
</div><p>While Solid Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Solid Biosciences 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

内部人士出售：Solid Biosciences（NASDAQ:SLDB）的首席技术官出售了 2,701 股股票